Replacement of neuraminidase inhibitor-susceptible influenza A(H1N1) with resistant phenotype in 2008 and circulation of susceptible influenza A and B viruses during 2009-2013, South Africa.
Amino Acid Substitution
Drug Resistance, Viral
/ genetics
Enzyme Inhibitors
/ pharmacology
Humans
Influenza A Virus, H1N1 Subtype
/ drug effects
Influenza A virus
/ drug effects
Influenza B virus
/ drug effects
Influenza, Human
/ virology
Inhibitory Concentration 50
Neuraminidase
/ antagonists & inhibitors
Oseltamivir
/ therapeutic use
Phenotype
Seasons
Sentinel Surveillance
South Africa
Viral Proteins
/ antagonists & inhibitors
Zanamivir
/ therapeutic use
South Africa
influenza
oseltamivir
susceptibility
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
01
03
2018
revised:
10
09
2018
accepted:
11
09
2018
pubmed:
16
9
2018
medline:
9
11
2019
entrez:
16
9
2018
Statut:
ppublish
Résumé
Data on the susceptibility of influenza viruses from South Africa to neuraminidase inhibitors (NAIs) are scarce, and no extensive analysis was done. We aimed to determine oseltamivir and zanamivir susceptibility of influenza A and B virus neuraminidases (NAs), 2007-2013, South Africa. We enrolled participants through national influenza-like illness surveillance, 2007-2013. Influenza diagnosis was by virus isolation and quantitative polymerase chain reaction (qPCR). Drug susceptibility was determined by chemiluminescence-based NA-STAR/NA-XTD assay. Sanger sequencing was used to determine molecular markers of NAI resistance. Forty percent (6341/15 985) of participants were positive for influenza viruses using virus isolation (2007-2009) and qPCR (2009-2013) methods. A total of 1236/6341 (19.5%) virus isolates were generated of which 307/1236 (25%) were tested for drug susceptibility. During 2007-2008, the median 50% inhibitory concentration (IC We confirm replacement of NAI susceptible by resistant phenotype influenza A(H1N1) in 2008. Influenza A and B viruses (2009-2013) remained susceptible to NAIs; therefore, these drugs are useful for treating influenza-infected patients.
Sections du résumé
BACKGROUND
Data on the susceptibility of influenza viruses from South Africa to neuraminidase inhibitors (NAIs) are scarce, and no extensive analysis was done.
OBJECTIVES
We aimed to determine oseltamivir and zanamivir susceptibility of influenza A and B virus neuraminidases (NAs), 2007-2013, South Africa.
PATIENTS/METHODS
We enrolled participants through national influenza-like illness surveillance, 2007-2013. Influenza diagnosis was by virus isolation and quantitative polymerase chain reaction (qPCR). Drug susceptibility was determined by chemiluminescence-based NA-STAR/NA-XTD assay. Sanger sequencing was used to determine molecular markers of NAI resistance.
RESULTS
Forty percent (6341/15 985) of participants were positive for influenza viruses using virus isolation (2007-2009) and qPCR (2009-2013) methods. A total of 1236/6341 (19.5%) virus isolates were generated of which 307/1236 (25%) were tested for drug susceptibility. During 2007-2008, the median 50% inhibitory concentration (IC
CONCLUSIONS
We confirm replacement of NAI susceptible by resistant phenotype influenza A(H1N1) in 2008. Influenza A and B viruses (2009-2013) remained susceptible to NAIs; therefore, these drugs are useful for treating influenza-infected patients.
Identifiants
pubmed: 30218485
doi: 10.1111/irv.12611
pmc: PMC6304311
doi:
Substances chimiques
Enzyme Inhibitors
0
Viral Proteins
0
Oseltamivir
20O93L6F9H
NA protein, influenza A virus
EC 3.2.1.18
Neuraminidase
EC 3.2.1.18
Zanamivir
L6O3XI777I
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-63Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCIRD CDC HHS
ID : U01 IP001048
Pays : United States
Organisme : CDC HHS
ID : 1U51IP000528
Pays : United States
Informations de copyright
© 2018 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
Influenza Other Respir Viruses. 2019 Jan;13(1):54-63
pubmed: 30218485
J Clin Virol. 2008 Jan;41(1):25-8
pubmed: 18055253
Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14
pubmed: 22203589
PLoS One. 2017 May 25;12(5):e0177655
pubmed: 28542324
Antiviral Res. 2004 Apr;62(1):37-45
pubmed: 15026200
J Antimicrob Chemother. 2006 Oct;58(4):723-32
pubmed: 16891631
Clin Infect Dis. 2010 Oct 15;51(8):983-4
pubmed: 20858074
J Virol Methods. 2010 May;165(2):254-60
pubmed: 20153377
Microbes Infect. 2006 Feb;8(2):511-9
pubmed: 16300986
Public Health Rep. 2013 Sep-Oct;128 Suppl 2:75-87
pubmed: 23997307
Virology. 2001 Oct 10;289(1):74-85
pubmed: 11601919
Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S36-43
pubmed: 21342897
J Infect Dis. 2012 Dec 15;206 Suppl 1:S159-65
pubmed: 23169964
J Infect. 2015 Feb;70(2):187-96
pubmed: 25224643
S Afr Med J. 2016 Feb 04;106(3):251-3
pubmed: 26915935
Antimicrob Agents Chemother. 2005 Nov;49(11):4515-20
pubmed: 16251290
J Infect Dis. 1998 Nov;178(5):1257-62
pubmed: 9780244
J Med Virol. 2004 May;73(1):71-8
pubmed: 15042651
PLoS Med. 2013 Nov;10(11):e1001558
pubmed: 24302890
Viruses. 2010 Oct;2(10):2269-89
pubmed: 21994620
Emerg Infect Dis. 2008 Nov;14(11):1809-10
pubmed: 18976580
PLoS One. 2014 Apr 15;9(4):e94681
pubmed: 24736452
N Engl J Med. 2009 Dec 3;361(23):2296-7
pubmed: 19907034
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Virus Res. 2004 Jul;103(1-2):61-6
pubmed: 15163490
Antiviral Res. 2015 May;117:27-38
pubmed: 25721488
BMC Infect Dis. 2010 Mar 08;10:56
pubmed: 20205961
J Trop Pediatr. 2012 Apr;58(2):102-6
pubmed: 21653546
Commun Dis Intell Q Rep. 2006;30(3):350-7
pubmed: 17120489
J Virol. 2006 Sep;80(17):8787-95
pubmed: 16912325
J Clin Microbiol. 2010 Mar;48(3):928-40
pubmed: 20089763
J Virol. 2012 Jan;86(1):11-8
pubmed: 22013031
J Infect Chemother. 2013 Oct;19(5):891-5
pubmed: 23529501
J Antimicrob Chemother. 2005 Feb;55(2):162-9
pubmed: 15665027
Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92
pubmed: 18625765
Antiviral Res. 2009 Jul;83(1):90-3
pubmed: 19501261
PLoS One. 2015 Mar 30;10(3):e0120226
pubmed: 25822719
BMC Public Health. 2014 Jan 16;14:41
pubmed: 24433304
J Infect Dis. 2012 Jul 15;206(2):148-57
pubmed: 22561367
J Infect Dis. 2011 Mar 15;203(6):838-46
pubmed: 21343149
J Infect Dis. 2011 Jan 1;203(1):25-31
pubmed: 21148493
S Afr Med J. 2008 Mar;98(3 Pt 2):224-30
pubmed: 18652399
Am J Trop Med Hyg. 2013 May;88(5):940-5
pubmed: 23458953
Antivir Ther. 2007;12(4 Pt B):603-16
pubmed: 17944268
J Clin Microbiol. 2003 Feb;41(2):742-50
pubmed: 12574276